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Abstract 
Introduction: Periodontal disease as a chronic inflammatory condition is more prevalent in adults. 
Considering the anti-inflammatory effect of statins and the need to find out the effects of these 
drugs on the prevention and treatment of periodontal diseases, this study was conducted to 
investigate the role of atorvastatin in periodontal health. 
Material & Methods: In this cross sectional study the effect of atorvastatin on plaque index, 
probing pocket depth (PPD), gingival index (GI) and bleeding on probing (BOP) index were 
examined. Patients with plaque index between 1 and 2 were included in the study, and those who 
had taken atorvastatin for at least 3 months were selected as the case group and those who had not 
taken atorvastatin were considered as the control group. 
Results: A total of 138 patients (50 patients for the atorvastatin group and 88 patients for the 
control group) were included. The mean probing pocket depth in the atorvastatin group was 
2.03±0.35 mm and that in the control group was 2.8±0.31 mm (p=0.335). The mean bleeding 
index in the atorvastatin group was 0.20±0.14 and compared to the control group was 0.20±0.17 
(p<0.001). The GI index in the atorvastatin group was 1.29±0.33, compared to the control group 
was 1.20±0.40 (p=0.218). 
Conclusion: The results of this study indicate the positive effect of the use of atorvastatin on 
reducing the bleeding on probing index in patients taking this drug. The probing pocket depth 
index and gingival index were not significantly different between the atorvastatin group and the 
group not taking this drug. 
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 چکیده
 بٍ ویبز ي َب استبتیه التُببی ضد اثر بٍ تًجٍ بب. است تر شبیغ بسرگسبلان در مٍ است التُببی سمهم بیمبریبیمبری پریًدوتبل  :مقدمه
آتًرياستبتیه در سلامت  اثر بررسی مىظًر بٍ مطبلؼٍ ایه پریًدوتبل، َبی بیمبری درمبن ي پیشگیری در داريَب ایه اثرات مردن پیدا
 پریًدوتبل اوجبم شد.
)، شبخص لثٍ DPP( پبمتاثر آتًرياستبتیه بر سلامت پریًدوتبل بب ارزیببی شبخص پلاك، ػمق بلؼٍ در ایه مط :ها مواد و روش
در مطبلؼٍ قرار گرفتىد ي افرادی  2تب  1) مًرد بررسی قرار گرفت. بیمبران بب شبخص پلاك بیه POBپريبیىگ ( حیه) ي خًوریسی IG(
د بٍ ػىًان گريٌ مًرد ي افرادی مٍ آتًرياستبتیه را مصرف ونردٌ بًدود بٍ مبٌ مصرف مردٌ بًدو 3مٍ آتًرياستبتیه را برای حداقل 
 ػىًان گريٌ شبَد در وظر گرفتٍ شدود.
در  پبمتبیمبر در گريٌ شبَد) شبمل می شدود. میبوگیه ػمق  99بیمبر در گريٌ آتًرياستبتیه ي  05بیمبر ( 931در مجمًع  :یافته ها
). میبوگیه شبخص خًوریسی در گريٌ 533.0 = pمیلیمتر بًد ( 2/9±0/13متر ي در گريٌ شبَد میلی  2/30±0/53گريٌ آتًرياستبتیه 
در گريٌ اتًرياستبتیه  IGشبخص p( > )100.0بًد،  0/02±0/11ي در مقبیسٍ بب گريٌ شبَد  0/02±0/41آتًرياستبتیه 
 ).812.0 = p( 1/02±0/04بًد در مقبیسٍ بب گريٌ شبَد  1/82±0/33
در بیمبران مصرف  حیه پريبیىگبر مبَش خًوریسی  وتبیج ایه مطبلؼٍ وشبن دَىدٌ تبثیر استفبدٌ از آتًرياستبتیه :نتیجه گیری
 تفبيت مردود ی مٍ ایه داري را مصرف ومیي گريَ آتًرياستبتیهبیه گريٌ  لثٍ ایي شبخص  پبمتمىىدٌ ایه داري است. ػمق 
 داری وداشت. مؼىی
 ، پریًدوتیت، َیپرلیپیدمیتًرياستبتیهآ واژگان کلیدی:
 
 noitcudortnI
-3 tibihni )srotibihni AOC-GMH( sgurd nitatS
 )AoC-GMH( A emyzneoc–lyratulglyhtem-3-yxordyH
 ehT ]1[ .yawhtap )AVM( etanolavem eht ni esatcuder
 ni eno cilobatem tnatropmi yrev a si AVM fo yawhtap
 ot sdael yletamitlu hcihw ,airetcab ynam dna setoyrakue
 sa hcus sdnuopmoc tnatropmi ynam fo noitcudorp eht
 enepocyl sa hcus senepret( sdionerposi dna loretselohc
 fo noisrevnoc eht ,revil namuh eht nI .)enetorac dna
-GMH yb decneulfni si dica cinolavem ot AoC-GMH
 fo segats laitini eht ni emyzne esatcuder AoC
 evititepmoc eht ,eroferehT .noitcudorp loretselohc
 doolb secuder sgurd citats yb emyzne siht fo noitibihni
 ot depoleved neeb evah snitatS ]2[ .slevel loretselohc
 slevel loretselohc mures rewol
]3[
 desu yllufsseccus dna 
 ]6-4[ .sesaesid yretra yranoroc taert dna lortnoc ot
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Recently, cholesterol-independent or “pleiotropic” 
effects of statins have attracted the most attention and it  
is expected that the anti-inflammatory pleiotropic  
effects result from the inhibition of isoprene modulation 
from an inflammatory signal transducer. [7, 8] Much 
attention has been paid to these potential effects 
including antithrombotic, antioxidant, anti-
inflammatory, anti-proliferative and immune 
modulatory effects. In addition, statins enhance the 
expression of the bone morphogenic protein-2 (BMP-2) 
and stimulate the proliferation of osteoblasts. [1] 
Furthermore, the decrease in LDL-C level, which is a 
pleiotropic characteristic of statins, indicates their anti-
inflammatory properties. 
[7, 9-13]  
Periodontal disease is 
caused by the function of certain microorganisms. 
Microorganisms and their products stimulate the 
inflammatory cells, produce cytokines, release 
proteolytic enzymes and activate osteoclasts. Although 
some studies have focused on the topical and systemic 
use of statins in the treatment of periodontal disease, 
many aspects of this disease still require further 
investigation. 
[5] 
Gingivitis is one of the most common 
topical inflammatory diseases in adults 
[14, 15]
, leading to 
periodontitis as a continuous inflammatory process that 
results in the destruction of periodontal tissue if left 
untreated. 
[16]
 This moderate inflammation can impose 
significant loads on the cardiovascular system, is 
involved in cardiovascular disease 
[16-19]
 and has been 
shown to be associated with systemic inflammation. 
[20] 
 
Since cardiovascular disease is also a common 
disease among adults, and various drugs including 
statins are administered for the prevention and treatment 
of their disease as well as considering the anti-
inflammatory effect of statins and the need to find out 
the effects of these drugs on the prevention and 
treatment of periodontal diseases, this cross-sectional 
study was performed to investigate the relationship 
between the use of atorvastatin and clinical symptoms 
of chronic periodontitis. 
 
 
Materials & Methods 
After ethical approval was given by Babol 
University of Medical Sciences 
(Mubabol.REC.1395.170). A total of 138 patients were 
selected from the patients admitted to Shahid Beheshti 
and Rouhani Hospitals of Babol University of Medical 
Sciences (Babol, Iran) and entered into the study. 
Patients were informed about the study process. To 
determine the anti-inflammatory pleiotropic effect of 
atorvastatin, the patients were divided into two groups, 
the first group included those who used 10 or 20 
mg/daily of atorvastatin for at least 3 months and the 
second group was those who did not use this drug with 
almost identical conditions. The patients were similar in 
terms of oral hygiene, and all of them regularly used 
toothbrushes.  
The patients' plaque index was examined and those 
with equal plaque indices (between 1 and 2) were 
compared in the current study. The two groups were 
equal in terms of age, ranging from 40 to 60 years and 
the exclusion criteria were smokers and patients with 
systemic diseases which affect periodontium, with the 
history of periodontal therapy for 6 months and with the 
history of antibiotic therapy since 1 month ago. The 
selected subjects in the atorvastatin group did not differ 
significantly in terms of the duration of this drug use. 
The indices were tested via examination on 
Ramfjord teeth using a periodontal probe, catheter and 
mirror. These teeth were the maxillary right first 
molar, maxillary left first incisor, maxillary left first 
premolar, mandibular left first molar, mandibular right 
first incisor and mandibular right first premolar .
[21]
 All 
of the patients were examined in the hospitals using a 
steady flashlight. Information such as age, gender, 
smoking and statin use were collected from the patients' 
records before they were examined. The patients' history 
of other diseases including diabetes mellitus and 
rheumatoid arthritis as well as history of the use of other 
medications were recorded. 
The plaque index was performed based on the Loe 
and Silness method. 
[22]
 The total score of each tooth 
was divided into 4 and the plaque index of each subject 
was obtained by adding the plaque index of all 
examined teeth and dividing it into the number of the 
examined teeth. The plaque index was between 0 and 3. 
It was evaluated in patients and was equal in both case 
and control groups, and finally, only those who had the 
plaque index between 1 and 2 were included in the 
present study. The probing pocket depth (PPD) or the 
distance from the gingival margin to the most coronal 
level of the junctional epithelium was measured using 
a probe on the Ramfjord teeth in the six areas of 
Mesiobuccal, Midbuccal, Distobuccal, Distolingual, 
Midlingual, and Mesiolingual. 
[21]
 
The gingival index (GI) was performed based on the 
Loe and Silness method. 
[22]
 The total score of each 
tooth is divided into 4 and the gingival index of each 
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subject is obtained by adding the gingival index of all 
examined teeth and dividing it into the number of the 
examined teeth. In this index, based the average of the 
obtained numbers, the status of the gingivitis is 
classified into three mild, moderate and severe degrees. 
The bleeding on probing (BOP) index was 
performed based on Barnett's proposed method. In this 
method, the periodontal probe slowly moved in the 
gingival sulcus at the buccal and lingual surfaces, the 
duration needed for bleeding was measured, the sum of 
the indicators of the 4 surfaces of the 6 teeth examined 
is divided into 24 and the obtained bleeding index of 
each patient was a number between 0 and 3. 
[23] 
Independent-sample t-test and paired-sample t-test 
were used to compare the data of the two groups using 
SPSS 21. P<0.05 was statistically considered as a 
significant difference. 
 
Results 
A total of 138 patients were entered into the present 
study. The atorvastatin group included 50 patients with 
an average age of 49.12±4.58 years and the control 
group was 88 patients with an average age of 
48.95±3.55 years.  
Table 1 shows the mean periodontal pocket depth in 
teeth 1, 4 and 6 for both atorvastatin and control groups. 
In general, the mean periodontal pocket depth in the 
atorvastatin group was 2.33±0.35 mm, whereas it was 
2.8±0.31 mm in the control group, which was not 
significant between the two groups (p=0.335).  
There was no significant difference between two 
groups in pocket depth according to the Mann-Whitney 
test. 
 
Table 1. The mean )±SD) periodontal pocket depth 
for atorvastatin and control groups 
 
Pvalue control 
group 
Atorvastatin 
Group 
Mean periodontal 
pocket depth and 
standard deviation 
per millimeters 
0.555 0.29±1.59 0.32±1.56 Tooth 1 
0.556 0.40±2.05 0.45±2.01 Tooth 4 
0.472 0.53±2.62 0.58±2.54 Tooth 6 
0.335 0.31±2.08 0.35±2.03 Total 
 
The mean scores of the bleeding on probing index 
for tooth 6 in the atorvastatin group and control group 
were 0.24±0.24 and 0.26±0.30, respectively. This mean 
score according to the Mann-Whitney test two groups 
was not statistically significant (p=0.718). 
The bleeding index for tooth 4 in the atorvastatin 
group was 0.15±0.17, while it was 0.28±0.25 in the 
control group, which was statistically significant 
(p=0.003). The results suggested that the mean score of 
the bleeding index was higher in control group than 
atorvastatin group. The mean (±SD) of bleeding index 
for tooth 1 in the atorvastatin group was 0.21±0.24, but 
it was 0.35±0.32 in the control group (p=0.014). The 
mean bleeding index in the atorvastatin group was 
0.20±0.14, whereas it was 0.20±0.17 in the control 
group (p<0.001).  
The mean GI index was 1.29±0.33 and 1.20±1.40 in 
the atorvastatin and control groups, respectively, 
indicating no statistically significant difference 
(p=0.132). Frequency and percentage of the GI index in 
both groups are presented in table 2. 
Table 2. Frequency and percentage of the GI index 
in both groups 
 
control 
group 
Atorvastatin 
Group 
 
65 
79.3% 
43 
87.8% 
frequency 
percentage 
mild GI 
index 
17 
20.7% 
12.2% frequency 
percentage 
moderate 
 
Discussion 
Periodontal disease is a chronic inflammatory 
disease characterized by the release of cytokines such as 
TNF-α and IL-1β. [24-27] Several studies have been 
conducted to investigate the possible association 
between serum lipid profile and periodontitis. 
[20, 27-33]
 
Nevertheless, investigations on the optimal role of statin 
drugs in periodontal tissues have led to controversial 
reports in some studies. 
[27, 32, 33]
 A retrospective study 
conducted by Lindy et al. 
[34]
 illustrated that the use of 
statin drugs was significantly associated with fewer 
symptoms of periodontal inflammatory injuries. Other 
studies have indicated that the serum pre-inflammatory 
cytokines and tissue fluid may be responsible for the 
relationship between periodontal disease and 
hyperlipidemia. 
[35-37]
 
The present study aimed at evaluating the 
periodontal health in patients taking atorvastatin and 
pocket depth index between the two groups. The results 
indicated no significant difference between the mean 
pocket depth in the atorvastatin group and control 
 Rezaei Talarposhti K, et al. 
34  Caspian J Dent Res-September 2018: 7(2): 30-37 
group. Lindy et al. and Sangwan et al. compared the 
pocket depth between patients taking and patients not 
taking statins .
[34, 38]
 Both studies demonstrated a 
significant difference between the two groups in terms 
of this index, which is inconsistent with the findings of 
the present study.  
This cross sectional study also showed that the 
difference of bleeding index between the atorvastatin 
group and the control group was significant so that the 
bleeding index was significantly higher in the control 
group than atorvastatin group. Moreover, a study 
conducted by Sayar et al. 
[39]
 illustrated that the 
hyperlipidemia patients treated with statin drugs for at 
least 3 months had a better periodontal status compared 
to those in the control group in terms of periodontal 
clinical parameters such as the bleeding on probing 
index. This positive effect of statin on the bleeding 
index and other clinical parameters of periodontal 
disease was similarly indicated in other studies. 
[34, 38-44] 
A comparison of the GI parameter between the two 
groups showed that the difference in this parameter is 
not statistically significant, which is consistent with the 
result of Sangwan et al. 
[38]
 Since statins have anti-
inflammatory effects, it can be construed that this lack 
of difference between the two groups is indicative of the 
positive effect of atorvastatin on maintaining the 
inflammatory status of the gingiva in the group taking 
this drug. However, the level of inflammatory proteins 
or other inflammatory markers has not been measured in 
the current study and this suggestion is based on 
previous studies conducted on the effect of statins on 
inflammation through measurement of inflammatory 
markers, histological analysis and genetic evaluation. 
[45, 
46] 
Several known biological characteristics of lipids 
may be responsible for the periodontal changes 
observed and in some cases, may explain the role of 
periodontal protection by statins in this study. The first 
explanation is that the improved serum lipid levels as a 
result of using the atorvastatin can be useful for 
periodontal tissues, because higher levels of lipid lead to 
relatively weaker situation of the periodontal status. 
[20, 
28-31]
 The hyperlipidemia status accelerates the pre-
inflammatory status and the decreased lipid levels of 
serum as a result of using the atorvastatin can by itself 
be effective in modulating inflammation. 
[47-50]
 The 
second explanation is that the direct pleiotropic effect of 
atorvastatin can lead to apparent benefits of periodontal 
health.  
This hypothesis is supported by previous studies, 
representing that the statins reduce the matrix 
metalloproteinase stimulated release 
[51]
, tumor 
necrosis factor (TNF-α) and C-reactive protein 
(CRP). [52] The pharmacokinetic analysis of statins has 
estimated plasma accumulation of about 10
-9
 and 10
-7
 
mol in recipients of oral systemic doses 
[53]
 and shown 
that the drug level in the tissue fluid of the gum is nearly 
10-100 times as much as plasma. 
[54]
 As a result, the 
topical anti-inflammatory effects on the oral tissue can 
be expected after oral administration of clinical doses. 
Although both of the described mechanisms can 
synergistically lead to the observed effects, the direct 
interpretation of the information obtained from this 
study cannot be linked to any of these mechanisms 
precisely, because the patients' serum lipid levels as 
well as inflammatory factors have not been measured 
due to the existing limitations. The results of the present 
study should be interpreted based on the limitations that 
the researchers encountered. The first limitation was the 
cross-sectional type of this research, explaining the 
cause-effect relationship.  
Another limitation was related to the lack of access 
to the baseline periodontal status data before the patients 
started taking atorvastatin. Despite the fact that all 
patients had a clear range of atorvastatin treatment 
duration, the exact period of each patient treated with 
this drug was not statistically analyzed for the 
interpretation of the results. In addition, periodontal 
indicators were evaluated only on four surfaces of 
Ramfjord teeth. 
 
 
Conclusion 
The results of this study indicate that the use of 
atorvastatin can be effective in reducing the bleeding on 
probing index in patients who use this medication. The 
pocket depth index and GI were not significantly 
different between atorvastatin users and non-users. 
Since statins have anti-inflammatory effects, this lack of 
difference between the two groups can be interpreted to 
indicate the beneficial effect of atorvastatin on 
maintaining the gingivitis in the group using this 
medication. 
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